Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pomalidomide
Find trials that include:  Any drugs shown
Results 1-25 of 30 for your search:
Start Over
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CC-4047-MM-007, NCI-2013-00024, NCT01734928
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-183, NCI-2015-01850, 163146, 2015-002509-13, NCT02576977
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AMyC 10-MM-01, NCI-2012-01279, IST-CAR-521, PO-MM-PI-0034, NCT01464034
Pomalidomide in Treating Patients with Kaposi Sarcoma with or without HIV
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-C-0047, NCI-2013-01525, 120047, P11847, PO-KS-NCI-0050, NCT01495598
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB12-1088, NCI-2012-01168, IRB12-1088-CR003, MMRC-048, MMRC# 048 / U Chicago protocol IRB#12-1088, NCT01665794
Bendamustine Hydrochloride, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00040206, NCI-2013-00480, MM-PI-0045, PO-MM-PI-0045, NCT01754402
Pomalidomide, Dexamethasone, and Filgrastim in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0018, NCI-2014-01270, NCI-2014-00159, NCT01946152
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-MM-102, NCI-2014-00978, NCT01997840
Pomalidomide and Dexamethasone with or without Ixazomib in Treating Patients with Refractory Multiple Myeloma
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A061202, NCI-2013-01702, CALGB-A061202, NCT02004275
Ixazomib plus Pomalidomide and Dexamethasone in Treating Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12267, NCI-2014-00803, 116980, NCT02119468
Pembrolizumab, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1454GCC, NCI-2015-01784, GCC1454 / HP-00061522, HCR-HP-00061522-1, HP-00061522, NCT02289222
Ixazomib Citrate with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Refractory Multiple Myeloma
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#253, NCI-2015-00575, 728937, IISR-2013-M100097, MLN9708, PO-TR-MM-PI-004614, X16043, NCT02542657
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1138-CA, NCI-2015-01756, PCI-32765, NCT02548962
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: STML-401-0414, NCI-2016-00108, NCT02661022
Pomalidomide in Treating Patients with Chronic Graft-versus-Host Disease
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 to 75
Trial IDs: 12-C-0197, NCI-2013-01552, 120197, P12974, NCT01688466
Clarithromycin, Pomalidomide and Dexamethasone with or without Stem Cell Transplant in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-138, NCI-2012-02936, NCT01745588
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients with Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1487, NCI-2015-01481, NCT02547662
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiply Myeloma and Impaired Renal Function (POM Renal)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CC-4047-MM-008, NCI-2012-00966, NCT01575925
Pomalidomide and Dexamethasone in Treating Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1281, NCI-2012-01948, NCT01722305
Pomalidomide, Bortezomib, and Dexamethasone as First-Line Treatment in Treating Patients with Amyloid Light-Chain Amyloidosis or Light Chain Deposition Disease
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-155, NCI-2012-02228, PO-AMYL-PI-0022, NCT01728259
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR103015, NCI-2014-02217, 2013-003491-12, 54767414MMY1001, NCT01998971
Pomalidomide after Combination Chemotherapy in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 9524, NCI-2013-02426, J13128, NA_00089739, NCT02029950
SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TCD14079, NCI-2015-00804, U1111-1155-7484, NCT02283775
Start Over